Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8223092 | 1.00 | EPHX2 (0.36) | EPHX2NAMPTPOLBEPHX1ATM | |
| SCHEMBL13282349 | 1.00 | EPHX2 (0.36) | EPHX2NAMPTPOLBEPHX1ATM | |
| SCHEMBL10137434 | 0.88 | ATM (0.33) | EPHX2NAMPTPOLBATM | |
| SCHEMBL13186124 | 0.88 | ATM (0.33) | EPHX2NAMPTPOLBATM | |
| SCHEMBL13321815 | 0.88 | POLB (0.50) | EPHX2POLB | |
| SCHEMBL19263835 | 0.82 | EPHX2 (0.37) | EPHX2NAMPTPOLBEPHX1ATM | |
| Acetic Acid SCHEMBL5502504 | 0.81 | — | — | |
| SCHEMBL2617044 | 0.81 | MAPT (0.38) | EPHX2NAMPTPOLB | |
| SCHEMBL76462 | 0.81 | — | — | |
| SCHEMBL13165462 | 0.81 | MAPT (0.38) | EPHX2NAMPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| US-RE49686-E1 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-10 | — | — | US | disclosed |
| US-RE49686-E1 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-10 | — | — | US | disclosed |
| US-RE48334-E1 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-12-01 | — | — | US | disclosed |
| US-8357654-B2 | Multimeric CD40 ligands, method for preparing same and use thereof for preparing drugs | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-01-22 | — | — | US | disclosed |
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-07-21 | — | — | US | disclosed |
| US-20100183642-A1 | NOVEL MULTIMERIC CD40 LIGANDS, METHOD FOR PREPARING SAME AND USE THEREOF FOR PREPARING DRUGS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-07-22 | — | — | US | disclosed |
| US-20100136034-A1 | NOVEL MULTIMERIC MOLECULES, A PROCESS FOR PREPARING THE SAME AND THE USE THEREOF FOR MANUFACTURING MEDICINAL DRUGS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-06-03 | — | — | US | disclosed |
| EP-1828240-B1 | NOVEL MULTIMERIC CD40 LIGANDS, METHOD FOR PREPARING SAME AND USE THEREOF FOR PREPARING DRUGS | CENTRE NAT RECH SCIENT (FR) | 2009-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | NTSR2, BDKRB1, AVPR1B | EPHX2 1713/4885NAMPT 2122/4885POLB 3271/4885 |
| US-20100183642-A1 | NOVEL MULTIMERIC CD40 LIGANDS, METHOD FOR PREPARING SAME AND USE THEREOF FOR PREPARING DRUGS | CD40, CD40LG, TNFSF10 | EPHX2 1289/4885NAMPT 2904/4885POLB 3609/4885 |
| US-20100136034-A1 | NOVEL MULTIMERIC MOLECULES, A PROCESS FOR PREPARING THE SAME AND THE USE THEREOF FOR MANUFACTURING MEDICINAL DRUGS | TNFRSF1A, TNFRSF9, CD40 | EPHX2 967/4885NAMPT 3192/4885POLB 3362/4885 |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | SREBF1, SREBF2, NR1H3 | EPHX2 703/4885NAMPT 1557/4885POLB 4003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.